-
JP Morgan Raises PT On Medtronic
Monday, January 24, 2011 - 8:17am | 27JP Morgan has raised the price target on Medtronic, Inc. (NYSE: MDT) from $38 to $39 and maintains its Neutral rating.
-
JP Morgan Raises PT On Medtronic
Monday, January 24, 2011 - 8:17am | 27JP Morgan has raised the price target on Medtronic, Inc. (NYSE: MDT) from $38 to $39 and maintains its Neutral rating.
-
Piper Jaffray Raises PT On Clinical Data
Monday, January 24, 2011 - 7:59am | 28Piper Jaffray has raised the price target on Clinical Data, Inc. (NASDAQ: CLDA) from $23 to $31 and maintains its Overweight rating.
-
Wells Fargo Downs STJ To Market Perform
Monday, January 24, 2011 - 7:55am | 44Analysts at Wells Fargo downgrade St. Jude Medical Inc (NYSE: STJ) from “outperform” to “market perform.” STJ shares gained 0.85% to close at $42.56 on Friday. More Analyst Ratings here
-
Rodman & Renshaw Opens CLDA With Outperform
Monday, January 24, 2011 - 7:08am | 52Analysts at Rodman & Renshaw initiate coverage of Clinical Data Inc (NASDAQ: CLDA) with an “outperform” rating. The target price for CLDA is set to $46. CLDA shares gained 1.28% to close at $15.03 on Friday. More Analyst Ratings here
-
510 (k) Reform: FDA's Blueprint - Analyst Blog
Friday, January 21, 2011 - 4:31pm | 1188In a major move, the U.S. Food and Drug Administration (“FDA”) have outlined a plan on January 19 consisting of 25 proposals, which it intends to implement during 2011 to improve the regulatory approval pathway for medical devices. Most of these proposals, announced by the FDA's Center for...
-
510 (k) Reform: FDA's Blueprint - Analyst Blog
Friday, January 21, 2011 - 3:49pm | 1188In a major move, the U.S. Food and Drug Administration (“FDA”) have outlined a plan on January 19 consisting of 25 proposals, which it intends to implement during 2011 to improve the regulatory approval pathway for medical devices. Most of these proposals, announced by the FDA's Center for...
-
Goldman Sachs Comments on Intuitive Surgical's 4Q10 Earnings (ISRG)
Friday, January 21, 2011 - 11:00am | 159Goldman Sachs is out with its report today on Intuitive Surgical (NASDAQ: ISRG) following ISRG's report of 4Q10 earnings yesterday. In a note to clients, GS writes, "On Thursday, January 20, Intuitive Surgical reported 4Q2010 EPS of $3.02 (+54.7% y/y), which was $0.67 better than our forecast and $...
-
Intuitive Surgical Trading Up 14.43% (ISRG)
Friday, January 21, 2011 - 10:39am | 26Intuitive Surgical, Inc. (NASDAQ: ISRG) is trading up 14.43% today. Shares last traded at $ 331.64, up from $289.83 at yesterday's close.
-
Intuitive Beats Zacks Estimates - Analyst Blog
Friday, January 21, 2011 - 10:31am | 782Intuitive Surgical (ISRG) reported fourth quarter and fiscal 2010 earnings per share of $3.02 and $9.47, respectively, beating the Zacks Consensus Estimates of $2.26 and $8.71, respectively, while surpassing the corresponding year-ago results of $1.95 and $5.93. Revenues Intuitive reported...
-
Estimates And PT Raised On Intuitive Surgical Corporation By Morgan Keegan
Friday, January 21, 2011 - 10:05am | 162Morgan Keegan has published a research report on Intuitive Surgical Corporation (NASDAQ: ISRG) after the company reported solid 4Q earnings and guidance for 2011. In the report, Morgan Keegan writes "Intuitive Surgical reported strong 4Q results with both revenue and EPS exceeding Street estimates...
-
Intuitive Beats Zacks Estimates - Analyst Blog
Friday, January 21, 2011 - 9:45am | 782Intuitive Surgical (ISRG) reported fourth quarter and fiscal 2010 earnings per share of $3.02 and $9.47, respectively, beating the Zacks Consensus Estimates of $2.26 and $8.71, respectively, while surpassing the corresponding year-ago results of $1.95 and $5.93. Revenues Intuitive reported...
-
Morgan Keegan Raises PT On Intuitive Surgical Corporation
Friday, January 21, 2011 - 9:23am | 29Morgan Keegan has raised the price target on Intuitive Surgical Corporation (NASDAQ: ISRG) from $285 to $300 and maintains its Market Perform rating.
-
Morgan Keegan Raises PT On Intuitive Surgical Corporation
Friday, January 21, 2011 - 9:23am | 29Morgan Keegan has raised the price target on Intuitive Surgical Corporation (NASDAQ: ISRG) from $285 to $300 and maintains its Market Perform rating.
-
J.P. Morgan Maintains ISRG Neutral Rating, $280 PT
Friday, January 21, 2011 - 9:12am | 172J.P. Morgan is maintaining its Neutral rating and $280 PT on Intuitive Surgical, Inc. (NASDAQ: ISRG). “Following several med tech pre-announcements, the comfort factor into 4Q results had increased, but the key debate, in our view, was about procedure guidance, which came in at 25-28% (vs. our 28%...